The Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "American Ac...
May 03 2019 - 7:00AM
PRESS RELEASE
Lund Sweden, May 3, 2019 -
Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that data from
the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease
has been selected to be presented orally by Global Coordinating
Principal Investigator, Dr Ralf Reilmann at the scieintific
conference "American Academy of Neurology (AAN)" in Philadelphia,
PA, May 4-10. The presentation titled "The efficacy and safety
results of laquinimod as a treatment for Huntington's Disease
(LEGATO-HD)" will be held on May 6 at 2 p.m. local time.
The abstract will be available on Active Biotech's website
(www.activebiotech.com) in connection with the
presentation.
ABOUT LEGATO-HD
LEGATO-HD is
a multinational, multicenter, randomized, double-blind,
placebo-controlled, parallel-group Phase 2 study of laquinimod as a
potential treatment in patients with HD. The study was designed to
evaluate three doses arms (0.5mg, 1.0mg, and 1.5mg daily) versus
placebo. The highest dose of 1.5 mg was discontinued in January
2016 as a precautionary measure after cardiovascular safety
problems were observed in multiple sclerosis studies with
laquinimod of 1.2 mg and 1.5 mg respectively. No similar issues
were identified in the LEGATO-HD study.
The primary endpoint evaluating the change from baseline at month
12 in the UHDRS-TMS for the 1.0 mg dose as compared with placebo
was not achieved. The secondary endpoint, percent change in brain
atrophy (caudate volume) from baseline at 12 months in the 1.0 mg
dose as compared to placebo, was met. The safety profile in the
study was similar to that expected in the patient
population.
Exploratory outcome includes change of Unified Huntington's Disease
Rating Scale - Total Motor Score (UHDRS-TMS) and percentage change
in brain atrophy for the 0.5 mg dose, as well as changes in
measured motor function (Q-motor), cognitive function, functional
capacity and brain volumes for the 1.0 and 0.5 mg doses
individually. The safety measures included adverse event reporting,
clinical laboratory tests, vital signs, electrocardiograms,
physical examinations and suicidality.
Results from the study have previously been presented at the
scientific conferences in the autumn of 2018 "Huntington Study
Group, HSG 2018" and "European Huntington's Disease Network (EHDN
)" annual meeting.
The study was conducted by Teva in collaboration with the
Huntington Study Group and European Huntington's Disease Network.
The study is registered as NCT02215616 on clinicaltrials.gov and
its EudraCT number is
2014-000418-75.
Lund May 3, 2019
Active Biotech AB (publ)
For further information, please contact:
Helén Tuvesson, CEO
Tel +46 46 19 21 56Email:
helen.tuvesson@activebiotech.com
Hans Kolam, CFO
Tel +46 46 19 20 44
Email: hans.kolam@activebiotech.com
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties in development for neurodegenerative
diseases. ANYARA (naptumumab), an immunotherapy, in development for
cancer indications in partnership with NeoTX Therapeutics Ltd.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(org.nr 556223-9227)
Box 724, 220 07 Lund
Tel. +46 46 19 20 00
The information
was submitted for publication at 13.00
p.m. CET on May 3, 2019.
Presentation
LEGATO-HD_AAN
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Sep 2023 to Sep 2024